3''-Chloro-6-[3-(4-cyano-benzyl)-3H-imidazol-4-ylmethoxymethyl]-biphenyl-3-carbonitrile

ID: ALA186906

Chembl Id: CHEMBL186906

PubChem CID: 44394953

Max Phase: Preclinical

Molecular Formula: C26H19ClN4O

Molecular Weight: 438.92

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  N#Cc1ccc(Cn2cncc2COCc2ccc(C#N)cc2-c2cccc(Cl)c2)cc1

Standard InChI:  InChI=1S/C26H19ClN4O/c27-24-3-1-2-22(11-24)26-10-21(13-29)8-9-23(26)16-32-17-25-14-30-18-31(25)15-20-6-4-19(12-28)5-7-20/h1-11,14,18H,15-17H2

Standard InChI Key:  JQBCZQXINWOHEL-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA186906

   3''-chloro-6-(((1-(4-cyanobenzyl)-1H-imidazol-5-yl)methoxy)methyl)biphenyl-3-carbonitrile

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 438.92

Molecular Weight (Monoisotopic): 438.1247

AlogP: 5.71

#Rotatable Bonds: 7

Polar Surface Area: 74.63

Molecular Species: NEUTRAL

HBA: 5

HBD: ┄

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 5.99

CX LogP: 5.29

CX LogD: 5.27

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.37

Np Likeness Score: -1.08

References

1. Lin NH, Wang L, Wang X, Wang GT, Cohen J, Gu WZ, Zhang H, Rosenberg SH, Sham HL..  (2004)  Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.,  14  (20): [PMID:15380198] [10.1016/j.bmcl.2004.07.083]

2. Li Q, Wang GT, Li T, Gwaltney SL, Woods KW, Claiborne A, Wang X, Gu W, Cohen J, Stoll VS, Hutchins C, Frost D, Rosenberg SH, Sham HL..  (2004)  Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.,  14  (21): [PMID:15454229] [10.1016/j.bmcl.2004.08.011]

3. Vaidya M, Weigt M, Wiese M..  (2009)  3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.,  44  (10): [PMID:19515462] [10.1016/j.ejmech.2009.04.045]

4. Puntambekar DS, Giridhar R, Yadav MR..  (2008)  Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.,  43  (1): [PMID:17448576] [10.1016/j.ejmech.2007.02.003]

Source

Source(1):

• Scientific Literature